Alphabet Inc. Buys Shares of 2,412,471 Maze Therapeutics, Inc. (NASDAQ:MAZE)

Alphabet Inc. bought a new stake in Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 2,412,471 shares of the company's stock, valued at approximately $26,561,000. Maze Therapeutics accounts for approximately 1.7% of Alphabet Inc.'s portfolio, making the stock its 13th biggest position. Alphabet Inc. owned approximately 5.51% of Maze Therapeutics at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. General Catalyst Group Management LLC acquired a new position in shares of Maze Therapeutics during the 1st quarter worth $11,405,000. Bessemer Group Inc. acquired a new position in shares of Maze Therapeutics during the 1st quarter worth $5,305,000. Bank of New York Mellon Corp acquired a new position in shares of Maze Therapeutics during the 1st quarter worth $190,000. Finally, New York State Common Retirement Fund acquired a new position in shares of Maze Therapeutics during the 1st quarter worth $25,000.

Maze Therapeutics Stock Up 4.9%

Shares of Maze Therapeutics stock traded up $0.80 on Thursday, hitting $17.06. The company's stock had a trading volume of 130,376 shares, compared to its average volume of 117,618. Maze Therapeutics, Inc. has a 52-week low of $6.71 and a 52-week high of $17.41. The business has a fifty day moving average of $12.17.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($1.15) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.39).

Wall Street Analyst Weigh In

MAZE has been the topic of a number of recent analyst reports. Guggenheim reaffirmed a "buy" rating and set a $19.00 price target on shares of Maze Therapeutics in a research note on Wednesday, April 2nd. Wedbush initiated coverage on shares of Maze Therapeutics in a research note on Tuesday, July 8th. They set an "outperform" rating and a $17.00 price target on the stock. Four investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $23.50.

Maze Therapeutics Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.